Statement re Media Article
Statement re Media Article
York, U.K. 8 February 2021: Abingdon Health plc (AIM: ABDX) ("the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, notes the article published in the Daily Mail on 6 February 2021 and refers investors to the RNS announcements made on 29 December 2020, 26 January 2021 and 27 January 2021 which accurately reflect the Company's position and current performance.
Abingdon Health plc
Chief Executive Officer
Chief Financial Officer
Sole Broker and Nominated Adviser
Shaun Dobson, Peter Steel,
Tel: +44 (0) 20 7496 3000
Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Tel: +44 (0) 7720 088 468
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
BrainCool AB (publ): BrainCool omstrukturerar för att öka flexibiliteten och planerar byte till Nasdaq First North under Q2 2022
All hänförlig personal, patent, varumärken och rättigheter samt väsentliga avtal överförs. I samband med omstruktureringen kommer Christian Strand, som är ansvarig för affärsutveckling inom BrainCool, utses till tf VD för CoolPrevent AB. VD kommer att bilda en ledningsgrupp med styrelseledamöterna R...
Framtagning av lågtiter blodgrupp 0 helblod: Presentation av resultat vid SABM 2021 (översättning)
Översättning av PM SEP 24, 2021 17:15 CET:Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting Glycorex Transplantation AB (publ.), noterat på NGM Main Regulated Equity, meddelar att Transfusionenheten vid University of R...
Voluntis announces its results for the first half of 2021
Decline in commercial invoicing to€ 1.5 million and IFRS revenue to€ 1.3 million in H1 2021 Significant increase in deferred revenues to€ 11.6 million at 30 June 2021 Significant reduction in operational expenses as part of the strategic roadmap announced in Marc...
Voluntis annonce ses résultats du 1er semestre 2021
Recul des facturations commerciales à 1,5 million d'euros et du chiffre d'affaires IFRS à 1,3 million d'euros au 1er semestre 2021 ; Progression sensible des produits constatés d'avance à 11,6 millions d'euros au 30 juin 2021; Réductio...